Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Novartis and Legend Biotech Sign Exclusive License Agreemen

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Nov 16, 2023 4:02pm

136 Views

Post# 35739964

RE:RE:RE:RE:RE:RE:RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen

You're the true trailblazer! I've been saying it the whole time.

Our drug is great and management has underperformed. It's been said multiple times. What has or hasn't happened isn't important.

If management doesn't sort themselves out there must be repercussions from the shareholders.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders